Overview of Efalizumab Open-label Trials

Article

An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.

Related Videos
Related Content

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023

Julie Harper, MD to Present a Rosacea Research Roundup and Pearls

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Make the Most of Your Visit to Asheville for Maui Derm NP + PA Fall 2023

September 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: Are You Attending Maui Derm NP+PA Fall 2023?

September 26th 2023

Journal Digest: September 26

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.